Martínez López, JoaquínDe La Cruz, JavierGil Manso, RodrigoAlegre Amor, AdriánOrtiz, JavierLlamas, PilarMartínez Díez, YolandaHernández Rivas, José ÁngelGonzález Gascón y Marín, IsabelBenavente Cuesta, CelinaEstival Monteliu, PabloJiménez Yuste, VíctorCanales Albendea, Miguel ÁngelBastos Oreiro, Mariana BeatrizKwon Kim, MiValenciano, SusanaCallejas Charavia, MartaLópez Jiménez, JavierHerrera Puente, PilarDuarte, RafaelNúñez Martín Buitrago, LucíaSánchez Godoy, PedroJacome Yerovi, CristinaMartínez Barranco, PilarGarcía Roa, MaríaEscolano Escobar, CristianMatilla García, ArturoRosado Sierra, BelénAláez Usón, María ConcepciónQuiroz Cervantes, KeinaMartínez Chamorro, CarmenPérez Oteyza, JaimeMartos Martinez, RafaelHerráez, ReginaGonzález Santillana, ClaraDel Campo, Juan FranciscoAlonso, AranchaFuente, Adolfo de laPascual, AdrianaBustelos Rodriguez, RosalíaSebrango, AnaRuiz Mediavilla, ElenaMarcheco-Pupo, Eriel AlexisGrande, CarlosCedillo, ÁngelLumbreras Bermejo, Carlos JuanArroyo Barea, AndrésCasas Rojo, Jose ManuelCalbacho Robles, MariaDíez Martín, José LuisGarcía Suárez, Julio2023-06-222023-06-222023Martínez López, J., De La Cruz, J., Gil Manso, R. et al. «COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study». Cancers, vol. 15, n.o 5, febrero de 2023, p. 1497. DOI.org (Crossref), https://doi.org/10.3390/cancers15051497.2072-669410.3390/cancers15051497https://hdl.handle.net/20.500.14352/72298Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February–June 2020; n = 769 (66%)) and later (July 2020–February 2021; n = 397 (34%)) cohorts. Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11–0.20. The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01–3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22–0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81–1.5). Among evaluable patients, 27.3% had post COVID-19 condition. These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/cancers15051497https://www.mdpi.com/journal/cancersopen access616.15616.155.392616.98:578.834578.834:616.98COVID-19SARS-CoV-2Hematological malignanciesMultiple myelomaLymphomaAcute leukemiaHematologíaMedicina interna3205.04 Hematología3205 Medicina Interna